|
CHMFL-BMX-078
|
化合物CHMFL-BMX-078
|
1808288-51-8
|
|
(±)-Zanubrutinib
|
(±)-贊魯替尼
|
1633350-06-7
|
|
Bosutinib
|
伯舒替尼
|
380843-75-4
|
|
Nilotinib
|
尼羅替尼
|
641571-10-0
|
|
Btk inhibitor 2
|
Btk inhibitor 2
|
1558036-85-3
|
|
CSF1R-IN-1
|
CSF1R-IN-1
|
2095849-04-8
|
|
BMS-935177
|
化合物BMS-935177
|
1231889-53-4
|
|
Dasatinib hydrochloride
|
達沙替尼鹽酸鹽
|
854001-07-3
|
|
TG 100572 Hydrochloride
|
4-氯-3-[5-甲基-3-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-1,2,4-苯并三嗪-7-基]苯酚單鹽酸鹽
|
867331-64-4
|
|
AG 1295
|
酪氨酸磷酸化抑制劑AG1295
|
71897-07-9
|
|
Dovitinib lactate
|
多韋替尼乳酸鹽
|
692737-80-7
|
|
Masitinib mesylate
|
馬賽替尼
|
1048007-93-7
|
|
Motesanib
|
莫特塞尼
|
453562-69-1
|
|
Sunitinib Malate
|
蘋果酸舒尼替尼
|
341031-54-7
|
|
Sunitinib
|
舒尼替尼
|
557795-19-4
|
|
Vandetanib
|
凡德他尼
|
443913-73-3
|
|
Multi-kinase inhibitor 1
|
化合物MULTI-KINASE INHIBITOR I
|
778274-97-8
|
|
PD173074
|
PD173074
|
219580-11-7
|
|
Toceranib phosphate
|
托西尼布磷酸鹽
|
874819-74-6
|
|
Tirbanibulin dihydrochloride
|
5-[4-[2-(4-嗎啉基)乙氧基]苯基]-N-(苯基甲基)-2-吡啶乙酰胺鹽酸鹽
|
1038395-65-1
|
|
Tirbanibulin Mesylate
|
1080645-95-9
|
1080645-95-9
|
|
Ensartinib hydrochloride
|
2137030-98-7
|
2137030-98-7
|
|
Tyrosine kinase inhibitor
|
DCL000409(XL184)
|
1021950-26-4
|
|
PF-573228
|
6-[(4-((3-(甲磺?；?芐基)氨基)-5-三氟甲基嘧啶-2-基)氨基]-3,4-二氫-1H-喹啉-2-酮
|
869288-64-2
|
|
SU14813 maleate
|
5-[(Z)-(5-氟-1,2-二氫-2-氧代-3H-吲哚-3-亞基)甲基]-N-[(2S)-2-羥基-3-(4-嗎啉基)丙基]-2,4-二甲基-1H-吡咯-3-甲酰胺馬來酸鹽
|
849643-15-8
|
|
Ningetinib Tosylate
|
對甲苯磺酸寧格替尼
|
1394820-77-9
|
|
3-Hydroxy Midostaurin
|
CGP52421
|
179237-49-1
|
|
INDY
|
INDY
|
1169755-45-6
|
|
KB SRC 4
|
1-[3-[1-([1,1'-Biphenyl]-3-ylMethyl)-1H-1,2,3-triazol-5-yl]phenyl]-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine
|
1380088-03-8
|
|
SU16f
|
化合物 T16947
|
251356-45-3
|
|
PF-06465469
|
PF 06465469
Discontinued See A191400
|
1407966-77-1
|
|
Vorolanib
|
VOROLANIB
|
1013920-15-4
|
|
Acrizanib
|
化合物ACRIZANIB
|
1229453-99-9
|
|
Vecabrutinib
|
維卡布魯替尼
|
1510829-06-7
|
|
Lck inhibitor 2
|
3-[[4-[(5-羥基-2-甲基苯基)氨基]-2-嘧啶基]氨基]苯甲酰胺
|
944795-06-6
|
|
Osteogenic Growth Peptide (10-14)
|
OSTEOGENIC GROWTH PEPTIDE (10-14)
|
105250-85-9
|
|
N-Deshydroxyethyl Dasatinib
|
N-DESHYDROXY ETHYL DASATINIB
|
910297-51-7
|
|
BRD4 degrader AT1
|
2098836-45-2
|
2098836-45-2
|
|
dTRIM24
|
dTRIM24
|
2170695-14-2
|
|
BI-3663
|
BI-3663
|
2341740-84-7
|
|
BSJ-03-123
|
BSJ-03-123
|
2361493-16-3
|
|
PROTAC ERα Degrader-2
|
PROTAC ER Degrader-2
|
1351169-29-3
|
|
PROTAC RIPK degrader-2
|
PROTAC RIPK degrader-2
|
1801547-16-9
|
|
PROTAC RIPK degrader-6
|
2-[2-[2-[2][4-[(5-苯并噻唑基氨基)-6-[(1,1-二甲基乙基)磺?；鵠-7-喹啉基]氧基]乙氧基]甲氧基]乙基]乙氧基]-N-[2-(2,6-二氧代-3-哌啶基)-2,3-二氫-1-氧代-1H-異吲哚-4-基]-乙酰胺
|
2089205-64-9
|
|
SNIPER(BRD)-1
|
SNIPER(BRD)-1
|
2095244-54-3
|
|
PAC
|
PAC
|
2158322-33-7
|
|
MS4078
|
MS4078
|
2229036-62-6
|
|
MZP-54
|
MZP-54
|
2010159-47-2
|
|
MZP-55
|
MZP-55
|
2010159-48-3
|
|
dBET6
|
1950634-92-0
|
1950634-92-0
|
|
PROTAC BET Degrader-10
|
|
1957234-97-7
|
|
PROTAC BET degrader-2
|
PROTAC BET DEGRADER-2
|
2093388-33-9
|
|
A1874
|
A-1874;A 1874
|
2064292-12-0
|
|
VZ185
|
VZ185
|
2306193-61-1
|
|
PROTAC FLT-3 degrader 1
|
PROTAC FLT-3 DEGRADER 1
|
2230826-81-8
|
|
BETd-246
|
BETD-246
|
2140289-17-2
|
|
PROTAC FAK degrader 1
|
PROTAC FAK degrader 1
|
2301916-69-6
|
|
MT-802
|
MT-802
|
2231744-29-7
|
|
ZXH-3-26
|
ZXH 3-26
|
2243076-67-5
|
|
THAL-SNS-032
|
THAL-SNS-032
|
2139287-33-3
|
|
BI-4464
|
BI 4464)
|
1227948-02-8
|
|
NV03
|
化合物 T12271
|
2448341-58-8
|
|
CP-10
|
CP-10
|
2366268-80-4
|
|
PROTAC Bcl2 degrader-1
|
PROTAC Bcl2 degrader-1
|
2378801-85-3
|
|
PROTAC Mcl1 degrader-1
|
PROTAC MCL1 DEGRADER-1
|
2163793-38-0
|
|
SIAIS178
|
SIAIS178
|
2376047-73-1
|
|
KB02-JQ1
|
6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE-6-ACETAMIDE, N-[2-[2-[2-[[2-[[1-(2-CHLOROACETYL)-1,2,3,4-TETRAHYDRO-6-QUINOLINYL]OXY]ACETYL]AMINO]ETHOXY]ET
|
2384184-44-3
|
|
PROTAC BRD4 ligand-1
|
PROTAC BRD4 ligand-1
|
2313230-51-0
|
|
ARCC-4
|
ARCC-4
|
1973403-00-7
|
|
Cereblon modulator 1
|
CC-90009
|
1860875-51-9
|
|
CDK9-IN-10
|
4H-1-Benzopyran-4-one, 5,8-dihydroxy-2-phenyl-7-(phenylmethoxy)-
|
3542-63-0
|
|
Rogaratinib
|
羅加替尼
|
1443530-05-9
|
|
WEHI-345 analog
|
化合物 WEHI-345 ANALOG
|
1354825-62-9
|
|
Tyrosine kinase-IN-1
|
TYROSINE KINASE-IN-1
|
705946-27-6
|
|
PCI-33380
|
1022899-36-0
|
1022899-36-0
|
|
CNX-500
|
CNX-500
|
1202758-21-1
|
|
N-piperidine Ibrutinib hydrochloride
|
3-(4-phenoxyphenyl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
2231747-18-3
|
|
Androgen receptor antagonist 1
|
Androgen receptor antagonist 1
|
1338812-36-4
|
|
Desmorpholinyl Navitoclax-NH-Me
|
化合物DESMORPHOLINYL NAVITOCLAX-NH-ME
|
2365172-82-1
|
|
SJF620
|
SJF620
|
2376187-16-3
|
|
XZ739
|
|
2365172-19-4
|
|
PROTAC BRD4 Degrader-5
|
|
2409538-70-9
|
|
BSJ-03-204
|
化合物 T30600
|
2349356-09-6
|
|
BSJ-04-132
|
BSJ-04-132
|
2349356-39-2
|
|
Thalidomide
|
沙利度胺
|
50-35-1
|
|
ARV-825
|
CS-2252
|
1818885-28-7
|
|
Navitoclax-piperazine
|
ABT-263-piperazine
|
2143096-93-7
|
|
Ibrutinib-biotin
|
1599432-18-4
|
1599432-18-4
|
|
SU4312
|
SU 4312;NSC 86429;SU-4312;NSC-86429
|
5812-07-7
|
|
tBID
|
1639895-85-4
|
1639895-85-4
|
|
Rp-cAMPS triethylammonium salt
|
ADENOSINE 3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER, TRIETHYLAMMONIUM SALT
|
151837-09-1
|
|
Rp-cAMPS sodium salt
|
ADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT
|
142439-94-9
|
|
BPR1K871
|
1-(3-氯苯基)-3-(5-(2-((7-(3-(二甲基氨基)丙氧基)喹唑啉-4-基)氨基)乙基)噻唑-2-基)脲
|
2443767-35-7
|
|
TAK-659 hydrochloride
|
TAK-659 (HYDROCHLORIDE)
|
1952251-28-3
|
|
Conteltinib
|
CONTELTINIB (CT-707)
|
1384860-29-0
|
|
Lanraplenib succinate
|
Lanraplenib (succinate)
|
1800047-00-0
|
|
Tivozanib
|
替沃扎尼
|
475108-18-0
|
|
ENMD-2076
|
6-(4-甲基-1-哌嗪基)-N-(5-甲基-1H-吡唑-3-基)-2-[(1E)-2-苯乙烯基]-4-嘧啶胺
|
934353-76-1
|
|
Ibrutinib D5
|
伊布替尼布D5
|
1553977-17-5
|
|
A-770041
|
A-770041
|
869748-10-7
|